Post-earnings recap
Reported
Fri, Nov 9, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axsome Therapeutics reported a loss per share of $0.31, but did not provide revenue figures or future guidance. The stock reacted negatively, declining by 1.28%. Investors may be concerned about the lack of clarity regarding the company's future performance and strategic direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook due to the lack of specific guidance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future quarters.
The company remains focused on advancing its clinical programs.